Credit Suisse Group reiterated their neutral rating on shares of GlaxoSmithKline plc (LON:GSK) in a report published on Thursday, July 27th. They currently have a GBX 1,775 ($23.11) target price on the stock.

Several other equities research analysts have also commented on GSK. UBS AG set a GBX 1,600 ($20.84) price objective on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research note on Thursday, April 27th. Liberum Capital restated a buy rating and set a GBX 1,900 ($24.74) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 27th. Citigroup Inc. restated a neutral rating and set a GBX 1,700 ($22.14) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, July 25th. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research note on Thursday, March 30th. Finally, Kepler Capital Markets restated a reduce rating and set a GBX 1,520 ($19.79) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 27th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of GBX 1,726.38 ($22.48).

GlaxoSmithKline plc (GSK) opened at 1528.50 on Thursday. The firm’s market capitalization is GBX 74.71 billion. The company’s 50-day moving average price is GBX 1,611.14 and its 200 day moving average price is GBX 1,625.37. GlaxoSmithKline plc has a 52-week low of GBX 1,446.50 and a 52-week high of GBX 1,745.56.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Receives “Neutral” Rating from Credit Suisse Group” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/08/credit-suisse-group-reaffirms-neutral-rating-for-glaxosmithkline-plc-gsk-updated.html.

The firm also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.

In other news, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were purchased at an average price of GBX 1,599 ($20.82) per share, for a total transaction of £36,249.33 ($47,205.80). Also, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($22.05), for a total transaction of £81,602.60 ($106,267.22). Insiders have purchased 3,150 shares of company stock worth $5,054,075 in the last three months.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.